2025-09-04 - Analysis Report
Okay, here's a report analyzing RXRX (Recursion Pharmaceuticals Inc.) based on the data you provided.

## RXRX (Recursion Pharmaceuticals Inc.) Analysis

**Company Overview:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to discover and develop novel therapeutics.

### 1. Performance vs. S&P 500 (VOO)

*   **RXRX Cumulative Return:** -47.08%
*   **VOO Cumulative Return:** 38.27%
*   **Divergence:**
    *   Max: 35.8
    *   Min: -89.0
    *   Current: -89.0
    *   Relative Divergence: 0.0

**Analysis:** RXRX has significantly underperformed the S&P 500 (VOO) over the period examined.  The current divergence is at the lowest point in the analyzed data, indicating substantial underperformance relative to the benchmark. The relative divergence of 0.0 confirms that RXRX is performing at the very bottom of its historical range compared to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR  | MDD   | Alpha   | Beta  | Cap(B) |
|------------|-------|-------|---------|-------|--------|
| 2021-2023  | 5.0%  | 73.6% | -1.0%   | -0.1 | 4.3    |
| 2022-2024  | 0.0%  | 73.6% | -25.0%  | 0.1 | 3.0    |
| 2023-2025  | 4.0%  | 73.6% | -47.0%  | 0.1 | 2.0    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) fluctuates, showing modest positive growth in some periods, but is relatively low overall.
*   **MDD:** The Maximum Drawdown (MDD) is consistently high at 73.6% across all periods, indicating significant risk and potential for substantial losses.
*   **Alpha:** Alpha is negative and decreasing over time (-1.0% to -47.0%), suggesting underperformance relative to its expected return based on its risk (Beta).
*   **Beta:** Beta is close to zero, indicating that the stock's price is not strongly correlated with the market (S&P 500). This may reflect the unique factors influencing RXRX's performance rather than broad market movements.
*   **Cap:** The company's capitalization has decreased from 4.3B to 2.0B over the observed periods, which could reflect market devaluation.

### 2. Recent Stock Price Movement

*   **Current Price:** 4.6099
*   **Last Market Data:** {'price': 4.6173, 'previousClose': 4.66, 'change': -0.92}
*   **5-day Moving Average:** 4.779
*   **20-day Moving Average:** 5.1707
*   **60-day Moving Average:** 5.3875

**Analysis:** The stock price is currently below all three moving averages (5-day, 20-day, and 60-day), which generally suggests a downtrend. The recent market data shows a slight decrease in price compared to the previous close, reinforcing the short-term downward momentum.

### 3. Market Risk Indicators and Expected Return

*   **MRI (Market Risk Indicator):** 0.3403 (Low Risk)
*   **RSI (Relative Strength Index):** 30.95 (Approaching Oversold)
*   **PPO (Percentage Price Oscillator):** -1.27
*   **Hybrid Signal:** cash\_70%\_Sell 70.0% of holdings (3431 shares - Caution - MRI:0.34)
*   **Recent (20-day) Relative Divergence Change:** -2.5 (Negative - Short-term Decline)
*   **Expected Return:** -2695.3%

**Analysis:**

*   The MRI indicates a low-risk environment, but this should be interpreted cautiously given the company's specific performance.
*   The RSI is approaching oversold territory (typically below 30), which *could* signal a potential for a price rebound, but given other indicators, it might just reflect continued weakness.
*   The negative PPO suggests that the short-term moving average is below the long-term moving average, which is a bearish signal.
*   The "Hybrid Signal" suggests a strong sell recommendation with a high cash allocation, indicating significant caution is warranted.
*   The recent negative change in relative divergence confirms the short-term underperformance is continuing.
*   The extremely negative expected return (-2695.3%) suggests that, based on current data, the model predicts severe underperformance compared to the S&P 500, even with a long-term investment horizon.
*  The small change of the 'price' from  {'price': 4.6173, 'previousClose': 4.66, 'change': -0.92} does not show the specific issues, so i didn't reflect it.

### 4. Recent News & Significant Events

*   **[2025-09-01]:** Major business developments, regulatory changes, or market events.
*   **[2025-09-03]:** Analysts discussing performance and outlook in the context of industry trends and global economic factors.
*   **[2025-09-04]:** Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   **[2025-09-02]:** Market experts highlight both risks and opportunities, advising investors to monitor recent news.

**Analysis:** The news snippets suggest the company is experiencing significant events that are causing volatility. Analysts are actively discussing the company, and market experts are advising caution. This calls for careful monitoring of company announcements and further investigation of the specific news driving these events.

### 5. Recent Earnings Analysis

| Date       | EPS   | Revenue      |
|------------|-------|--------------|
| 2025-08-05 | -0.41 | 0.02 B$      |
| 2025-05-05 | -0.5  | 0.01 B$      |
| 2024-11-06 | -0.34 | 0.03 B$      |
| 2024-08-08 | -0.4  | 0.01 B$      |
| 2025-08-05 | -0.4  | 0.01 B$      |

**Analysis:** The company has consistently reported negative Earnings Per Share (EPS) across all listed quarters. Revenue fluctuates, but remains relatively low. This suggests that the company is currently not profitable.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-06-30 | $0.02B   | -5.54%        |
| 2025-03-31 | $0.01B   | -47.31%       |
| 2024-12-31 | $0.00B   | -183.62%      |
| 2024-09-30 | $0.03B   | 53.69%        |
| 2024-06-30 | $0.01B   | 36.14%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE       |
|------------|----------|-----------|
| 2025-06-30 | $0.92B   | -18.70%   |
| 2025-03-31 | $0.93B   | -21.68%   |
| 2024-12-31 | $1.03B   | -17.29%   |
| 2024-09-30 | $0.52B   | -18.27%   |
| 2024-06-30 | $0.58B   | -16.69%   |

**Analysis:**

*   **Revenue and Profitability:** Revenue is inconsistent and generally low. Profit margins are volatile, with significant losses in some quarters. The negative profit margins indicate that the company is spending more money than it is generating in revenue during those periods.
*   **Capital and Profitability:** Equity has fluctuated. Return on Equity (ROE) is consistently negative, indicating the company is not generating profits from shareholders' investments.

### 7. Overall Analysis and Summary

Based on the provided data, RXRX (Recursion Pharmaceuticals Inc.) appears to be facing significant challenges. Hereâ€™s a summary:

*   **Underperformance:** The stock has significantly underperformed the S&P 500.
*   **High Risk:** The high Maximum Drawdown suggests substantial risk.
*   **Negative Financials:** Consistent negative EPS, low and fluctuating revenue, negative profit margins, and negative ROE highlight profitability issues.
*   **Bearish Technical Indicators:** The stock price is below moving averages, the PPO is negative, and the Hybrid Signal suggests selling.  The RSI is approaching oversold territory, but this might not indicate an imminent rebound.
*   **Cautionary News:** Recent news and analyst discussions suggest the company is experiencing volatility and faces both risks and opportunities.
*   **Decreasing Alpha:** the Alpha decreasing indicate the stock underperforms comparing to market.

**Conclusion:**  The data paints a bearish picture for RXRX. The company is struggling with profitability, faces significant market challenges, and has consistently underperformed the broader market. The strong sell signal and negative expected return suggest that investors should exercise extreme caution. Further investigation into the specific events driving the volatility and a thorough review of the company's future prospects are warranted before making any investment decisions.
